Wonigeit K
J Clin Chem Clin Biochem. 1984 Dec;22(12):959-67.
Immunological rejection is still the most important problem in clinical organ transplantation requiring the lifelong immuno-suppressive treatment of the allograft recipient. The clinical success rate however can be improved by a variety of diagnostic procedures: The reduction of the histocompatibility barrier between donor and recipient by HLA-typing and organ exchange in order to obtain the best possible match; posttransplant monitoring of donor specific immune responsiveness towards donor antigens; monitoring of T-cell subsets by monoclonal antibodies and cytofluometry. T-cell subset monitoring is a rapidly developing new technique with great potential. With the presently available first generation reagents already a detailed analysis of the major T-cell population in circulation is possible, which can markedly facilitate the diagnosis of rejection and viral infection. New monoclonal antibodies, defining certain activation stages of T-cells or permitting a more refined differentiation of functionally distinct subsets will lead to increased relevance of this diagnostic approach. A particularly interesting aspect of monoclonal antibodies against T-cell differentiation antigens is their potential therapeutic use as immunosuppressive drugs with a highly selective action on defined T-cell subsets.
免疫排斥仍是临床器官移植中最重要的问题,这需要对同种异体移植受者进行终身免疫抑制治疗。然而,通过各种诊断程序可以提高临床成功率:通过 HLA 分型和器官交换来降低供体和受体之间的组织相容性屏障,以获得尽可能最佳的匹配;移植后监测供体特异性免疫反应对供体抗原的反应;通过单克隆抗体和细胞荧光测定法监测 T 细胞亚群。T 细胞亚群监测是一项快速发展且具有巨大潜力的新技术。利用目前可用的第一代试剂,已经能够对循环中的主要 T 细胞群体进行详细分析,这可以显著促进排斥反应和病毒感染的诊断。定义 T 细胞某些激活阶段或允许对功能不同的亚群进行更精细区分的新型单克隆抗体,将提高这种诊断方法的相关性。针对 T 细胞分化抗原的单克隆抗体一个特别有趣的方面是它们作为免疫抑制药物的潜在治疗用途,对特定的 T 细胞亚群具有高度选择性作用。